The combination also led to favorable changes in total cholesterol, fasting blood sugar, and a marker of inflammation.
Primary outcomes were disease severity and cognitive function, measured at baseline, every 2 weeks during the trial, and again at the end of the study. Measurement tools included the Positive and Negative Syndrome Scale for disease severity and the 30-point Montreal Cognitive Assessment for cognitive function.A total of 69 patients completed the trial, and no adverse effects were observed during the study period.
Like McIntyre, Palmer noted that larger clinical trials are needed before a treatment recommendation can be made.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: PreventionMag - 🏆 141. / 63 Read more »
Source: Medscape - 🏆 386. / 55 Read more »